HCW Biologics Inc. — Q1 2022 Form 10-Q Summary
Reporting period: Three months ended March 31, 2022; filed May 13, 2022. HCW Biologics is a pre-commercial biopharmaceutical company developing immunotherapies for age-related diseases. Revenue to date has principally come from its Wugen license and supply arrangements; it has no approved products or commercial product sales.
Financial results and position
| Metric | Q1 2022 | Q1 2021 / prior balance-sheet date |
|---|---|---|
| Revenue | $3.12 million | $0 |
| Cost of revenue / gross profit | $1.33 million / $1.79 million | Not applicable |
| Gross margin | About 57% | Not applicable |
| Research and development | $1.79 million | $2.33 million, down 23% |
| General and administrative | $1.88 million | $1.08 million, up 74% |
| Operating loss | $1.88 million | $3.41 million |
| Net loss | $2.06 million | $2.84 million |
| Basic and diluted loss per share | $0.06 | $0.69 |
| Cash used in operations | $1.59 million | $1.49 million |
At March 31, 2022, cash and cash equivalents were $18.1 million; short-term investments were $17.0 million; and the balance-sheet Investments line was $11.35 million. The filing describes approximately $9.8 million of Treasury notes and a $1.6 million Wugen investment within investments. Total assets were $51.0 million, total liabilities $1.56 million, and stockholders’ equity $49.4 million. No borrowings or other debt are reported. Operating lease liabilities totaled $307,000.
Management estimated available capital would fund operating expenses and contractual obligations until the end of 2023, but said additional capital will be needed to fully implement its plan. Q1 cash increased by $6.39 million, principally because $8.0 million of short-term investments matured; operating activities continued to consume cash.
Material changes and notable items
- Revenue of $3.12 million was recognized for Wugen development-supply materials after the parties entered statements of work under their master services agreement. No revenue was reported in Q1 2021; there was no deferred revenue at March 31, 2022.
- R&D expense declined mainly due to lower manufacturing/materials and preclinical spending. G&A rose primarily from public-company costs, insurance, higher professional services, and stock-based compensation, including an equity award to the CEO related to the IPO.
- Interest and other income shifted from $568,000 of income in Q1 2021 to a $176,000 loss in Q1 2022, including unrealized losses on investments. The prior-year period included a $567,000 gain from PPP loan forgiveness.
- In July 2021, the IPO generated approximately $49.2 million in net proceeds and triggered conversion of all preferred shares into common stock. The company reported 35.8 million common shares outstanding at March 31, 2022.
- The company adopted lease accounting effective January 1, 2022 and began two-year operating leases for its Miramar premises on March 1, 2022.
Outlook, risks, and contingencies
- Management expected HCW9218 to enter clinical development in the first half of 2022, including an investigator-sponsored Phase 1 solid-tumor trial and a company-sponsored Phase 1b trial in advanced pancreatic cancer. These are stated expectations, not reported trial outcomes.
- HCW9302 IND-enabling work was expected to be completed by the end of 2022, with an IND filing for a planned Phase 1b/2 autoimmune-disorder trial targeted for the first half of 2023. R&D and clinical expenses are expected to increase.
- Management said it may need additional equity financing or collaboration funding; if financing is inadequate, it may have to reevaluate its operating plan or delay product development. The runway estimate depends on assumptions that may prove incorrect.
- Future funding needs and timelines are subject to clinical, regulatory, enrollment, manufacturing, collaboration, and commercialization uncertainties. COVID-19 and its variants could disrupt trials or operations, and the company said the impact was uncertain.
- Future payments under third-party manufacturing agreements were approximately $2.1 million at quarter-end. Management reported no material pending legal proceedings; no material changes to previously disclosed risk factors were reported.
- Disclosure controls and procedures were assessed as effective, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether Wugen supply revenue is recurring, the timing of collections, and the degree of customer concentration.
- Actual clinical-trial starts, enrollment, safety findings, and progress against the stated HCW9218 and HCW9302 timelines.
- Whether management’s end-of-2023 capital runway estimate remains valid as clinical and manufacturing spending grows, and whether additional financing will be required.
- The composition and liquidity of reported investments, particularly the Wugen holding, which the filing says has limited liquidity until publicly traded.
- Remaining manufacturing commitments, revenue-recognition estimates for supply work, and the impact of investment-market changes on results.